Next Selection : February 9-10th 2021
Deadline for application: December 15th 2020
The name of possible thesis directors can be found in the list of participating laboratories on our website: http://www.unil.ch/cancer-immunology/home/menuinst/research-groups.html
For students interested in applying through the Track 2 procedure, they are encouraged to make a list of up to 5 choices, with the understanding that not all laboratories have open positions at a given time, and they may be considered by other faculty members with similar interests.
The applications have to be sent to : email@example.com
Prof. Laurent Perez, PhD
Faculty of Biology and Medicine
Immunology and Allergy (IAL) department
Ch. Des Boveresses 155
The Laboratory of Molecular Immunology (LMI), headed by Prof Laurent Perez is open to PhD candidates application :
The LMI investigates the mechanisms of antibody-mediated resistance to infectious diseases and antibody-antigen interactions. This research leads to direct translational medicine applications for immunoglobulin therapy and vaccine design. Recent publications of the group includes Marcandalli J, et al. Cell 2019 and Martinez-Martin N, et al. Cell 2018.
We are looking for a motivated, meticulous and curious PhD student. She/he will use modern molecular biology, biochemistry and immunology approaches to identify, sequence and express recombinant antibodies against infectious (or inflammatory) diseases and develop recombinant nanoparticles as protectives therapies against pathogens (or diseases) with an unmet medical need. Student will receive ample support from lab members and collaborators regarding both experimental and data analyses.
Candidates should hold a Master degree in immunology and molecular biology or other relevant discipline such as virology and biochemistry. Applicants with a pure immunological background that wish to gain experience in biochemistry and molecular biology are welcome to apply. Laboratory experience in one of the following approaches would be advantageous: biochemistry/biophysics (protein expression and interaction), molecular biology (RT-PCR, PCR), Electron Microscopy (negative staining), mice immunization or flow cytometry.
For application, please send:
- Short cover letter indicating research interests (1 page)
- Curriculum vitae (with e-mail address and phone number)
- Names and contact information of 2 references
Prof. Johanna Joyce
Department of Oncology, Ludwig Institute for Cancer Research, Lausanne
Objectives: Emerging evidence indicates that immune cells are mobilized and activated in the tumour microenvironment (TME) during metastatic cancer progression. The TME is also altered following various anti-cancer therapies, which can paradoxically contribute to a lack of response/ acquired resistance to treatment. In particular, inflammation can promote metastatic progression. We will systematically focus on different immune cell types whose levels vary across systemic inflammation, in specific tissues - including the brain, and whose variations are further exacerbated by the presence of a primary tumour. We will determine whether this translates to increased cancer metastasis to this site, and the potential dependency on specific cytokines or factors. Subsequent genetic, chemical or biological studies will follow to confirm the causality of these mechanisms to the metastatic phenotype. The underlying mechanistic contribution of the microenvironment to metastasis and therapeutic resistance will be based on a range of complementary techniques including mouse models of cancer, 3D co-culture systems, computational approaches, and analysis of patient samples in collaboration with our clinical colleagues.
Additional training opportunities: This project will be embedded within a metastasis-focused training network - Evomet. Evomet is funded by an EU-MSCA International Training Network grant, which includes labs across Europe. This is an excellent opportunity for an enthusiastic and motivated student to join the Lausanne site of the Evomet ITN, and to be part of this larger network with many training, research and education opportunities across the different locations. Applications are welcome from all over the world, but must not have resided in the host country (Switzerland in this case) during the previous 12 months, following the ITN directives to enhance international mobility of the student researchers.
Prof. Monika E. Hegi, PhD
Laboratory of Brain Tumor Biology and Genetics (LBGT)
Neurosurgery & Neuroscience Research Center
Department of Clinical Neurosciences, CHUV
Ch. Des Boveresses 155
Phone 021 314 2582
Project Proposal 2020
Targeting Pathway Vulnerabilities Induced by Epigenetic Disturbance in Glioblastoma
The laboratory works at the interphase of basic and clinical research in brain tumors. In the proposed project, we aim at identifying druggable vulnerabilities of cancer relevant pathways revealed upon disturbing the tumor cells by epigenetic drugs, such as Bromodomain inhibitors (BETi). BETi target chromatin readers such as BRD4 that regulate expression of proto-oncogenic genes. We have identified several gene signatures indicative of cancer relevant pathways that are disturbed upon treatment with BETi. Investigating the function of these genes/pathways mechanistically in in vitro models and with bio-informatics approaches, will inform on their suitability to serve, as targets for treatment and the biological function will guide the choice for the second drug to use. Hits will be tested for synergistic effects with BET inhibition. Successful combinations will be taken into patient derived orthotopic xenograft models in the mouse. Molecular biomarkers and magnetic resonance imaging/ spectroscopy based response markers will be developed for translation into the clinical setting. 1,2 3
1. Gusyatiner O, Hegi ME. Glioma epigenetics: From subclassification to novel treatment options. Semin Cancer Biol. 2018; 51:50-58.
2. Gusyatiner O, Pham MDT, Lei Y, et al. BET inhibitors synergize with HDAC inhibitors and downregulate expression of interferon response genes in glioblastoma. In: AACR, ed. 109th Annual Meeting of the American Association for Cancer Research, Abstr #2923. Vol 78. Chicago, Illinois: AACR; 2018.
3. Stathis A, Bertoni F. BET proteins as targets for anticancer treatment. Cancer Discov. 2018; 8(1):24-36.